Nilo Therapeutics launched with a $101 million Series A to advance preclinical programs that target neural circuits controlling systemic immunity. The company, founded by academic neuro‑immunology leaders, aims to develop small molecules that modulate vagal and other brain‑to‑body pathways to reset chronic inflammation in autoimmune and inflammatory diseases. Investors include The Column Group, DCVC Bio, Lux Capital and philanthropy arms; funding will build R&D labs, expand preclinical teams, and progress lead candidates toward IND‑enabling studies. Nilo’s approach leverages recent basic discoveries mapping discrete neuronal subsets that regulate peripheral immune responses, translating circuit biology into small‑molecule modalities. The financing highlights growing interest in neuro‑immune therapeutics as a category distinct from biologics and cell therapy—positioning neural‑circuit modulation as a potential platform for multiple immune indications if safety and specificity can be achieved.